http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 23 Sep 2026 04:48:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Innovent+to+Present+New+Clinical+Data+of+Next-gen+IO+and+ADC+Pipeline+at+the+2026+ESMO+Annual+Meeting/27092601.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and SUZHOU, <location value="LC/cn" idsrc="xmltag.org" >China</location></span>, <span class="legendSpanClass"><chron>Sept. 23, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its IBI363/TAK-928 (PD-1/IL-2^α-biased bispecific fusion protein)^* , IBI343/TAK-921 (Arcotatug Tavetecan, CLDN18.2 ADC)^*, IBI3001(EGFR/B7H3 ADC)^* , IBI354(HER2 ADC) and TYVYT® (sintilimab injection)^** will be presented http://www.streetinsider.com/Press+Releases/Innovent+to+Present+New+Clinical+Data+of+Next-gen+IO+and+ADC+Pipeline+at+the+2026+ESMO+Annual+Meeting/27092601.html Wed, 23 Sep 2026 04:48:00 -0400 IVBIY http://www.streetinsider.com/PRNewswire/Innovent+to+Present+New+Clinical+Data+of+Next-gen+IO+and+ADC+Pipeline+at+the+2026+ESMO+Annual+Meeting/27092601.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and SUZHOU, <location value="LC/cn" idsrc="xmltag.org" >China</location></span>, <span class="legendSpanClass"><chron>Sept. 23, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its IBI363/TAK-928 (PD-1/IL-2^α-biased bispecific fusion protein)^* , IBI343/TAK-921 (Arcotatug Tavetecan, CLDN18.2 ADC)^*, IBI3001(EGFR/B7H3 ADC)^* , IBI354(HER2 ADC) and TYVYT® (sintilimab injection)^** will be presented http://www.streetinsider.com/PRNewswire/Innovent+to+Present+New+Clinical+Data+of+Next-gen+IO+and+ADC+Pipeline+at+the+2026+ESMO+Annual+Meeting/27092601.html Wed, 23 Sep 2026 04:48:00 -0400 IVBIY http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/Press+Releases/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html <div class="xn-content"> <p class="prntac"><b>Transforming from Regional Leader to Global Premier: </b></p><p class="prntac"><b>A Clear Strategic Path for Growth and Globalization</b></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.</p> <p><b>Dr. <person>Michael Yu</person>, Founder, Chairman of the Board and CEO of Innovent, stated:</b> "Looking back over the past fifteen years, Innovent has completed http://www.streetinsider.com/PRNewswire/Innovent+Announces+2026+Interim+Results+and+Business+Updates/26970415.html Tue, 25 Aug 2026 06:15:00 -0400 01801 1801 6IB A.31066700 IVBIY O.22422661 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405 http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html <div class="xn-content"> <ul type="disc"><li>Collaboration to accelerate access to Vanflyta^® for patients with newly diagnosed <i>FLT3</i>-ITD positive AML</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >SAN FRANCISCO</location> and <location value="LU/cn..suzhou" idsrc="xmltag.org" >SUZHOU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 9, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics, Inc.</span> (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in <location value="LC/cn" idsrc="xmltag.org" >China</location>.</p> <p>Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta^® while <span value="HongKong:1801" idsrc="xmltag.org" >Innovent Biologics</span> holds sole commercialization rights for Vanflyta^® in <location value="LC/cn" idsrc="xmltag.org" >China</location>, leading market promotion.</p><p>VANFLYTA http://www.streetinsider.com/Press+Releases/Innovent+Biologics+and+Daiichi+Sankyo+Enter+Exclusive+Agreement+for+VANFLYTA%C2%AE+Commercialization+in+China/26892848.html Sun, 09 Aug 2026 20:00:00 -0400 1801 4568 6IB A.17568957 A.22847412 A.33615634 IVBIY O.03960636 O.04889877 O.07116439 O.39140405